Garrett v. Lynch, ARNP, Sarasota Pain Management

CourtDistrict Court of Appeal of Florida
DecidedJuly 10, 2026
Docket2D2025-1356
StatusPublished

This text of Garrett v. Lynch, ARNP, Sarasota Pain Management (Garrett v. Lynch, ARNP, Sarasota Pain Management) is published on Counsel Stack Legal Research, covering District Court of Appeal of Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Garrett v. Lynch, ARNP, Sarasota Pain Management, (Fla. Ct. App. 2026).

Opinion

DISTRICT COURT OF APPEAL OF FLORIDA SECOND DISTRICT

JULIA P. GARRETT, as Personal Representative of the Estate of Wyatt Dean Garrett, deceased,

Appellant,

v.

AGNES LYNCH, ARNP; SARASOTA PAIN MANAGEMENT; and PHYSICIAN PARTNERS OF AMERICA,

Appellees.

No. 2D2025-1356

July 10, 2026

Appeal from the Circuit Court for Hillsborough County; Jennifer X. Gabbard, Judge.

Jeffrey B. Crockett of Coffey Burlington, P.L., Miami, for Appellant.

Damien M. Hoffman and Mark E. McLaughlin of Beytin, McLaughlin, McLaughlin, Osborne, Brumby, Hoffman & Mirelman, P.A., Tampa, for Appellees Agnes Lynch, ARNP, and Physician Partners of America.

No appearance for remaining Appellee.

GUARD, Judge. In 2019, fentanyl killed 3,244 people in Florida. See MED. EXAM'RS COMM'N, DRUGS IDENTIFIED IN DECEASED PERSONS BY FLORIDA MEDICAL EXAMINERS, at ii (2019). That number constituted a thirty-eight percent increase in deaths compared to 2018. Id. Fentanyl caused more deaths in Florida than any other drug that year. Id. Wyatt Dean Garrett died in 2019. He did not die of a fentanyl overdose, and fentanyl did not cause his death in a manner reflected in those startling statistics. But he died, in part, because of the response to the opioid epidemic and the misprescribing and abuse of fentanyl by others. Garrett believed he needed fentanyl for his chronic pain and, when he could no longer get a prescription for it because of the tougher regulatory environment, he committed suicide. While his death is tragic, that tragedy does not translate into a duty owed under these circumstances. Accordingly, we affirm. I. This is a medical malpractice wrongful death case. Garrett served in the United States Army. He injured his back while deployed during Operation Desert Storm. He attempted to resolve that injury and relieve his chronic back pain by undergoing surgery, twice, with providers not involved in this case. Those surgeries failed to relieve his pain. At some time more than ten years before his death, Garrett became a patient at Sarasota Pain Management. While a patient at Sarasota Pain Management, Garrett received treatment from Dr. Chun and, after 2017, by Agnes Lynch. Dr. Chun owned Sarasota Pain Management and was its treating physician. Lynch was an Advanced Practice Registered Nurse, who was supervised by Dr. Chun. Dr. Chun prescribed Garrett two powerful fentanyl products to help Garrett with his back pain (1) Duragesic and (2) Actiq. Duragesic is a transdermal fentanyl patch that provides long-term pain relief for severe chronic pain for up to seventy- two hours. Actiq is a rapid-acting, short-lasting lollipop-like transmucosal fentanyl lozenge used to manage breakthrough cancer pain. The risk of overdose and addiction with Actiq is so severe that to prescribe it the Food and Drug Administration (FDA) mandates a

2 healthcare provider complete an additional course and become certified in the Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy Program (TIRF REMS). Dr. Chun was TIRF REMS certified. Lynch was not TIRF REMS certified. Indeed, Lynch did not and could not prescribe the opioids that Garrett received as she did not have a Drug Enforcement Administration Registration and Sarasota Pain Management did not authorize her to prescribe such medications even if she did. Garrett's Actiq prescription was "off-label," meaning it was prescribed to Garrett for a use that had not been officially approved by the FDA. Prescribing a medication for off-label use, in and of itself, is not unlawful or in any way wrong for a health care provider. See U.S. FOOD AND DRUG ADMIN., UNDERSTANDING UNAPPROVED USE OF APPROVED DRUGS

"OFF LABEL" (2018) (stating that "healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient"). The evidence is undisputed that Garrett had used Duragesic and Actiq for more than ten years without incident. Garrett had a monthly appointment with either Dr. Chun or Lynch. From 2017 until January 2019, Lynch saw Garrett five or six times. In 2018, Dr. Chun lowered the number of doses of Actiq that Garrett received. He did so because of "government regulations" and "government interventions" that were limiting somehow his ability to prescribe fentanyl. The record does not contain much detail relating to what regulations or interventions were causing Dr. Chun to reduce Garrett's Actiq prescription. There is no deposition of Dr. Chun in the record. The only things in the record relating to government pressure on Dr. Chun are Julia Garrett's testimony and lawyer commentary during

3 the depositions and the summary judgment hearing. Julia Garrett testified that one of Garrett's appointments was cancelled because the police were at Dr. Chun's office when they arrived. Her understanding was that the police were there and the office was closed because Dr. Chun overmedicated patients.1 And during multiple of the depositions and in arguments, the lawyers for both parties commented that Dr. Chun was indicted and convicted for receiving kickbacks related to a different fentanyl product, Subsys, and was sentenced to three and a half years in prison. It is unclear if the police at his office on the day Julia Garrett was there were related to Dr. Chun's criminal conviction or if Dr. Chun in 2018 was aware that he was under criminal investigation. While we do not have a deposition of Dr. Chun, we do have Dr. Chun's notes in Garrett's chart. In the notes for Garrett's June 2018 appointment, Dr. Chun raised to Garrett the possibility of Actiq being cutoff to Garrett to which Garrett allegedly stated that he would have a "heart attack" and would rather die than suffer the severe pain he would be in without Actiq. Similarly, in the notes of Garrett's July 2018 appointment, Dr. Chun again raised the possibility of Actiq being cutoff because of "government regulations facing us." This time Garrett purportedly stated that "he would rather die and commit suicide than live a life of such pain level." It does not appear that Dr. Chun did much in response to either comment. For example, Dr. Chun did not have Garrett evaluated or committed for suicidal ideation. Sometime in December 2018 through January 2019, Dr. Chun sold his practice to Physician Partners of America (PPOA). PPOA is a chain of pain management clinics in the United States. Dr. Chun did not

1 Julia Garrett believed that her husband was overmedicated by Dr.

Chun. 4 continue practicing at PPOA. Dr. James Adams replaced Dr. Chun and he became the doctor for Dr. Chun's former patients, including Garrett. Dr. Adams retained Lynch and began supervising her. Dr. Adams was not TIRF REMS certified. Lynch was unaware that Dr. Adams was not TIRF REMS certified until sometime after January 11, 2019. After taking over, Dr. Adams generally told Lynch that he wanted to alter the products prescribed away from opioid products, like Actiq, and reduce the morphine milligram equivalents (the strength of opioids) prescribed to Dr. Chun's former patients. On January 11, 2019, Garrett had his monthly appointment. He met with Lynch, not Dr. Adams. During his appointment, Lynch told Garrett that Dr. Adams planned to change his prescriptions away from Actiq and reduce the amount of opioids prescribed to Garrett. Garrett did not want his prescriptions changed, argued briefly with Lynch, and terminated his doctor-patient relationship with Lynch, Dr. Adams, and PPOA. Lynch documented his discharge and spoke to Dr. Adams. Her note stated "[d]ischarged from the practice related to not accepting changes of his pain medications." Despite not seeing Garrett, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McCain v. Florida Power Corporation
593 So. 2d 500 (Supreme Court of Florida, 1992)
Vargas v. Glades General Hosp.
566 So. 2d 282 (District Court of Appeal of Florida, 1990)
Paddock v. Chacko
522 So. 2d 410 (District Court of Appeal of Florida, 1988)
Drew v. Knowles
511 So. 2d 393 (District Court of Appeal of Florida, 1987)
Clay Elec. Co-Op., Inc. v. Johnson
873 So. 2d 1182 (Supreme Court of Florida, 2003)
Abel Limones, Sr. v. School District of Lee County
161 So. 3d 384 (Supreme Court of Florida, 2015)
Joseph S. Chirillo, Jr., M.D. v. Robert Granicz, etc.
199 So. 3d 246 (Supreme Court of Florida, 2016)
Rolando P. Ruiz, etc. v. Tenet Hialeah Healthsystem, Inc.
260 So. 3d 977 (Supreme Court of Florida, 2018)
Haslett v. Broward Health Imperial Point Medical Center
197 So. 3d 124 (District Court of Appeal of Florida, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Garrett v. Lynch, ARNP, Sarasota Pain Management, Counsel Stack Legal Research, https://law.counselstack.com/opinion/garrett-v-lynch-arnp-sarasota-pain-management-fladistctapp-2026.